Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

Inclusion Criteria

• •1. Newly diagnosed AML patients confirmed by bone marrow morphology and immunophenotyping.
• •2. Complete MICM (Morphology, Immunophenotyping, Cytogenetics, Molecular genetics) work-up.
• •3. Age ≥ 18 years.
• •4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• •5. Day 6 Peripheral Blood Blast Percentage (D6PBBP) ≥ 1%.
• •6. Renal function with creatinine clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula or measured by 24-hour urine collection).
• •7. Liver function with Aspartate Aminotransferase (AST) ≤ 2.5 × ULN\*; Alanine Aminotransferase (ALT) ≤ 2.5 × ULN\*; Total bilirubin ≤ 1.5 × ULN\* (\*Unless considered due to leukemia infiltration).
• •8. Patients deemed suitable to receive DA/IA therapy by the investigator.
• •9. Signed informed consent form. -
• •6. Severe cardiac disease, including congestive heart failure, myocardial infarction, or cardiac dysfunction.
• •7. Concurrent active malignancy of other organ systems (patients with a history of cured malignancy may be eligible).
• •8. Active tuberculosis or HIV-positive patients.
• •9. Concurrent other hematological disorders.
• •10. Pregnant or lactating women.
• •11. Inability to comprehend or comply with the study protocol.
• •12. Hypersensitivity to any component of the drugs involved in the protocol.
• •13. Inability to take oral medication or patients with malabsorption syndrome.
• •14. Uncontrolled systemic infection.
• •15. Prior venetoclax treatment and/or current participation in any other study involving investigational agents.